Palladio Biosciences, Inc., is a Centessa company. Their first product, lixivaptan, is in Phase 3 clinical development for the treatment of autosomal polycystic kidney disease (ADPKD). ADPKD causes numerous fluid-filled cysts to grow in both kidneys.  It is a life-limiting, chronic and progressive disease.

Biotechnology

Palladio Biosciences

Palladio Biosciences' headquarters in Horsham, PA, United States

Alex Martin

Amy Murnane

Linda C. Hogan

Marcus Abraitis

Lorenzo Pellegrini

Neil H. Shusterman

Palladio Biosciences' Leadership Team includes Neil H. Shusterman and 7 others.

About

People (8)

Alex Martin

Amy Murnane

Linda C. Hogan

Lorenzo Pellegrini

Marcus Abraitis

Milena Kanova

Neil H. Shusterman

Ron Dadino

Jobs